Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from InhaleRx Limited ( (AU:IRX) ).
InhaleRx Limited has secured strong shareholder backing at its 29 January general meeting, with all eight resolutions passed by poll, including the ratification of prior share issues, approvals for additional placement securities and options under an existing funding facility, and a change of the company’s name to Nexalis Therapeutics Limited. The broad support for these capital and governance measures reinforces the company’s funding base and strategic flexibility as it accelerates development of its inhaled and oral therapies for pain and mental health, positioning the renamed Nexalis Therapeutics to pursue U.S. regulatory pathways and address significant treatment gaps in these high-need markets.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical-stage drug development company focused on rapid-onset inhaled and oral therapies targeting unmet medical needs in pain management and mental health. Its key pipeline assets include IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder and SRX-25 for treatment-resistant depression, supported by a funding facility of up to $52.3 million to advance these programs toward U.S. FDA approval via accelerated regulatory pathways.
Average Trading Volume: 276,823
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.16M
See more insights into IRX stock on TipRanks’ Stock Analysis page.